Podcast Episodes

Back to Search
JPM26: Sunshine, AI and the deals that weren't
JPM26: Sunshine, AI and the deals that weren't

With this year’s iteration of the J.P. Morgan Healthcare Conference in the rearview mirror, the biopharma industry has officially closed the door on …

5 months, 2 weeks ago

Short Long
View Episode
From approval to value: Why evidence storytelling now matters (Sponsored)
From approval to value: Why evidence storytelling now matters (Sponsored)

As payers focus on long-term outcomes and real-world performance, value matters more than ever. RTI Health Solutions experts discuss how clear eviden…

5 months, 3 weeks ago

Short Long
View Episode
Drug approvals went from crawl to sprint in 2025
Drug approvals went from crawl to sprint in 2025

In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency could maintain its pace in …

5 months, 3 weeks ago

Short Long
View Episode
Putting patients first: from buzzword to business imperative (Sponsored)
Putting patients first: from buzzword to business imperative (Sponsored)

What does it really mean to put patients first in today’s life sciences landscape? In this sponsored episode of The Top Line, leaders from RTI Health…

5 months, 4 weeks ago

Short Long
View Episode
Beyond the AI hype: How life sciences can turn agents into a competitive advantage (Sponsored)
Beyond the AI hype: How life sciences can turn agents into a competitive advantage (Sponsored)

As artificial intelligence continues to dominate conversations across life sciences, many companies are reaching an inflection point between experime…

5 months, 4 weeks ago

Short Long
View Episode
China’s biotech moment goes global, Zai Lab exec says (Sponsored)
China’s biotech moment goes global, Zai Lab exec says (Sponsored)

China has moved from a fast-following biotech market to a source of globally competitive innovation, according to Josh Smiley, president and chief op…

5 months, 4 weeks ago

Short Long
View Episode
Biopharma CEOs assess the road ahead in 2026
Biopharma CEOs assess the road ahead in 2026

After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved.

A tough biotech investing environm…

6 months ago

Short Long
View Episode
A year in review and what 2026 holds for biopharma and healthcare
A year in review and what 2026 holds for biopharma and healthcare

As 2025 closes, biopharma and healthcare are learning to live on shifting ground. In this special year-end episode of "The Top Line," Fierce reporter…

6 months, 3 weeks ago

Short Long
View Episode
From data to decisions: how Walgreens is powering smarter pharma strategies (Sponsored)
From data to decisions: how Walgreens is powering smarter pharma strategies (Sponsored)

Walgreens is emerging as a real-world evidence partner for the biopharma industry, according to a new episode of The Top Line, sponsored by Walgreens…

7 months ago

Short Long
View Episode
The biopharma dealmaking landscape and what to expect in 2026
The biopharma dealmaking landscape and what to expect in 2026

Uncertainty reigned early this year with the inauguration of President Donald Trump and his threats to impose tariffs and slash prescription drug pri…

7 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us